secwatch.observer — SEC 8-K summary
======================================

Issuer:     Marker Therapeutics, Inc. (MRKR)
CIK:        0001094038
Form:       8-K/A
Filed at:   2025-03-04T23:59:59+00:00
Accession:  0001104659-25-020405
Event type: other_material
Sentiment:  neutral
Materiality: 0.25
Item codes: 5.02, 8.01, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

Marker Therapeutics corrects option grant date to Feb 12, 2025; awards options to CEO and directors
--------------------------------------------------------------------------------

- CEO Dr. Juan Vera receives 50,000 stock options vesting annually over three years.
- Non-employee directors David Eansor, Katherine Knobil, Steven Elms each receive 30,000 options.
- Amendment corrects prior filing: grant date changed from Feb 12, 2024 to Feb 12, 2025.
- All options are under the 2020 Omnibus Stock Ownership Plan and standard award agreement.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1094038/000110465925020405/0001104659-25-020405-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1094038/000110465925020405/tm258250d1_8ka.htm
  HTML page:      https://secwatch.observer/filing/0001104659-25-020405

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer